Single‐Dose Pharmacokinetics of Sodium Ferric Gluconate Complex in Iron‐Deficient Subjects
- 1 May 2004
- journal article
- clinical trial
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 24 (5), 574-583
- https://doi.org/10.1592/phco.24.6.574.34750
Abstract
Study Objectives. To determine the single‐dose pharmacokinetics of intravenous sodium ferric gluconate complex in sucrose injection (SFGC) in iron‐deficient human volunteers, and to assess iron transport. Design. Open‐label, randomized study. Setting. Clinical research facility. Subjects. Fourteen iron‐deficient men and women. Interventions. Subjects were randomized to receive a single intravenous dose of either SFGC 62.5 mg administered over 30 minutes or SFGC 125 mg over 60 minutes. Five days later, the same subjects were rerandomized to receive a second intravenous dose of SFGC, either 62.5 mg administered over 4 minutes or 125 mg over 7 minutes. Measurements and Main Results. Blood samples were collected at predefined times before, during, and up to 72 hours after the infusion to determine the single‐dose pharmacokinetics of SFGC. Assays were performed for both total iron and transferrin‐bound iron, from which drug‐bound iron could be calculated. Urine was collected over 24 hours before dosing and for 24 hours after the start of infusion to determine the renal elimination of iron. Clearance of SFGC from serum was rapid and far exceeded rates reported for iron dextran. Pharmacokinetic parameters were unaffected by dose or infusion rate. Serum iron derived from SFGC did not exceed the binding capacity of transferrin. Serum iron from SFGC became rapidly available (< 24 hrs) as transferrin‐bound iron, but only after passage through another compartment, presumably the reticuloendothelial system (RES). At least 80% of the administered iron was transported to bone marrow within 24 hours after infusion. Conclusions. Iron derived from SFGC appears to be rapidly transferred to a bioavailable iron compartment as transferrin‐bound iron after digestion in the RES. At the doses administered in this study, liberation of potentially toxic, free iron was not detectable.Keywords
This publication has 18 references indexed in Scilit:
- Chronic use of sodium ferric gluconate complex in hemodialysis patients: Safety of higher-dose (≥250 mg) administrationAmerican Journal of Kidney Diseases, 2003
- Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patientsKidney International, 2003
- Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextranKidney International, 2002
- IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000American Journal of Kidney Diseases, 2001
- Serum ferritin: Does it differ from tissue ferritin?Journal of Gastroenterology and Hepatology, 1996
- 'Oversaturation' of transferrin after intravenous ferric gluconate (FerrlecitR) in haemodialysis patientsNephrology Dialysis Transplantation, 1996
- Efficacy of oral iron therapy in patients receiving recombinant human erythropoietinAmerican Journal of Kidney Diseases, 1995
- Acute Iron PoisoningAmerican Journal of Diseases of Children, 1980
- Iron Balance in Hemodialysis PatientsAnnals of Internal Medicine, 1977
- Determination of serum iron and Latent Iron-Binding Capacity (LIBC)Clinica Chimica Acta; International Journal of Clinical Chemistry, 1971